Production (Stage)
Mineralys Therapeutics, Inc.
MLYS
$16.12
$0.503.20%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -107.62% | -147.31% | -170.85% | -195.48% | -160.63% |
| Total Depreciation and Amortization | 525.00% | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 340.36% | 206.98% | 65.78% | -22.36% | -532.29% |
| Change in Net Operating Assets | -271.67% | 227.47% | 672.78% | 369.16% | 2,119.16% |
| Cash from Operations | -120.09% | -104.89% | -105.93% | -93.30% | -147.15% |
| Capital Expenditure | 37.29% | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 202.57% | 171.70% | 122.85% | 70.68% | 53.02% |
| Cash from Investing | 202.44% | 171.64% | 122.76% | 70.64% | 52.98% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 62.71% | -42.81% | -42.82% | -42.69% | -42.76% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -506.35% | -- | 63.67% | 78.70% | 96.13% |
| Cash from Financing | 63.28% | -42.86% | -42.54% | -42.24% | -63.74% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 255.95% | 268.73% | -70.61% | -22.72% | -139.15% |